245 related articles for article (PubMed ID: 37382806)
1. Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer.
Meißner AK; Gutsche R; Galldiks N; Kocher M; Jünger ST; Eich ML; Nogova L; Araceli T; Schmidt NO; Ruge MI; Goldbrunner R; Proescholdt M; Grau S; Lohmann P
J Neurooncol; 2023 Jul; 163(3):597-605. PubMed ID: 37382806
[TBL] [Abstract][Full Text] [Related]
2. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
3. Radiomics for the noninvasive prediction of the BRAF mutation status in patients with melanoma brain metastases.
Meißner AK; Gutsche R; Galldiks N; Kocher M; Jünger ST; Eich ML; Montesinos-Rongen M; Brunn A; Deckert M; Wendl C; Dietmaier W; Goldbrunner R; Ruge MI; Mauch C; Schmidt NO; Proescholdt M; Grau S; Lohmann P
Neuro Oncol; 2022 Aug; 24(8):1331-1340. PubMed ID: 34935978
[TBL] [Abstract][Full Text] [Related]
4. A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC.
Chen M; Lu H; Copley SJ; Han Y; Logan A; Viola P; Cortellini A; Pinato DJ; Power D; Aboagye EO
J Thorac Oncol; 2023 Jun; 18(6):718-730. PubMed ID: 36773776
[TBL] [Abstract][Full Text] [Related]
5. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma.
Peng J; Zou D; Zhang X; Ma H; Han L; Yao B
J Transl Med; 2024 Jan; 22(1):87. PubMed ID: 38254087
[TBL] [Abstract][Full Text] [Related]
6. A Machine Learning Approach Using PET/CT-based Radiomics for Prediction of PD-L1 Expression in Non-small Cell Lung Cancer.
Lim CH; Koh YW; Hyun SH; Lee SJ
Anticancer Res; 2022 Dec; 42(12):5875-5884. PubMed ID: 36456151
[TBL] [Abstract][Full Text] [Related]
7. Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC.
Wang C; Ma J; Shao J; Zhang S; Li J; Yan J; Zhao Z; Bai C; Yu Y; Li W
Front Immunol; 2022; 13():828560. PubMed ID: 35464416
[TBL] [Abstract][Full Text] [Related]
8. [Construction of A Nomogram Prediction Model for PD-L1 Expression
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
Hao L; Wang L; Zhang M; Yan J; Zhang F
Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
[TBL] [Abstract][Full Text] [Related]
9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
10. Machine learning-based radiomics strategy for prediction of cell proliferation in non-small cell lung cancer.
Gu Q; Feng Z; Liang Q; Li M; Deng J; Ma M; Wang W; Liu J; Liu P; Rong P
Eur J Radiol; 2019 Sep; 118():32-37. PubMed ID: 31439255
[TBL] [Abstract][Full Text] [Related]
11. Predicting PD-L1 expression status in patients with non-small cell lung cancer using [
Zhao X; Zhao Y; Zhang J; Zhang Z; Liu L; Zhao X
EJNMMI Res; 2023 Jan; 13(1):4. PubMed ID: 36682020
[TBL] [Abstract][Full Text] [Related]
12. Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images.
Wang C; Ma J; Shao J; Zhang S; Liu Z; Yu Y; Li W
Front Immunol; 2022; 13():813072. PubMed ID: 35250988
[TBL] [Abstract][Full Text] [Related]
13. A CT-based radiomics signature for preoperative discrimination between high and low expression of programmed death ligand 1 in head and neck squamous cell carcinoma.
Zheng YM; Zhan JF; Yuan MG; Hou F; Jiang G; Wu ZJ; Dong C
Eur J Radiol; 2022 Jan; 146():110093. PubMed ID: 34890937
[TBL] [Abstract][Full Text] [Related]
14. Multiparameter spectral CT-based radiomics in predicting the expression of programmed death ligand 1 in non-small-cell lung cancer.
Zheng XX; Ma YQ; Cui YQ; Dong SS; Chang FX; Zhu DL; Huang G
Clin Radiol; 2024 Apr; 79(4):e511-e523. PubMed ID: 38307814
[TBL] [Abstract][Full Text] [Related]
15. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients.
Farina B; Guerra ADR; Bermejo-Peláez D; Miras CP; Peral AA; Madueño GG; Jaime JC; Vilalta-Lacarra A; Pérez JR; Muñoz-Barrutia A; Peces-Barba GR; Maceiras LS; Gil-Bazo I; Gómez MD; Ledesma-Carbayo MJ
J Transl Med; 2023 Mar; 21(1):174. PubMed ID: 36872371
[TBL] [Abstract][Full Text] [Related]
16. Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors.
Sperduto PW; De B; Li J; Carpenter D; Kirkpatrick J; Milligan M; Shih HA; Kutuk T; Kotecha R; Higaki H; Otsuka M; Aoyama H; Bourgoin M; Roberge D; Dajani S; Sachdev S; Gainey J; Buatti JM; Breen W; Brown PD; Ni L; Braunstein S; Gallitto M; Wang TJC; Shanley R; Lou E; Shiao J; Gaspar LE; Tanabe S; Nakano T; An Y; Chiang V; Zeng L; Soliman H; Elhalawani H; Cagney D; Thomas E; Boggs DH; Ahluwalia MS; Mehta MP
Int J Radiat Oncol Biol Phys; 2022 Sep; 114(1):60-74. PubMed ID: 35331827
[TBL] [Abstract][Full Text] [Related]
17. CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study.
Jiang Z; Dong Y; Yang L; Lv Y; Dong S; Yuan S; Li D; Liu L
J Digit Imaging; 2021 Oct; 34(5):1073-1085. PubMed ID: 34327623
[TBL] [Abstract][Full Text] [Related]
18. Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients.
Bracci S; Dolciami M; Trobiani C; Izzo A; Pernazza A; D'Amati G; Manganaro L; Ricci P
Radiol Med; 2021 Nov; 126(11):1425-1433. PubMed ID: 34373989
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy.
Hulsbergen AFC; Mammi M; Nagtegaal SHJ; Lak AM; Kavouridis V; Smith TR; Iorgulescu JB; Mekary RA; Verhoeff JJC; Broekman MLD; Phillips JG
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):258-267. PubMed ID: 32335185
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Tumor PD-L1 Expression in Resectable Non-Small Cell Lung Cancer by Machine Learning Models Based on Clinical and Radiological Features: Performance Comparison With Preoperative Biopsy.
Hashimoto K; Murakami Y; Omura K; Takahashi H; Suzuki R; Yoshioka Y; Oguchi M; Ichinose J; Matsuura Y; Nakao M; Okumura S; Ninomiya H; Nishio M; Mun M
Clin Lung Cancer; 2024 Jan; 25(1):e26-e34.e6. PubMed ID: 37673781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]